GenSight Biologics Closes EUR 1 Million Fundraising Backed by Existing Shareholders

GenSight Biologics closed its EUR 1 million fundraising, announced October 8, 2026, with support from existing shareholders. The offering included 2,597,404 ordinary shares, admitted to trading on Euronext Paris on October 12, 2026. It also included 11,940,300 pre-funded warrants exercisable for 11,940,300 additional ordinary shares. A further 14,537,704 investor warrants give holders the right to subscribe to 7,268,852 additional ordinary shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gensight Biologics SA published the original content used to generate this news brief on October 16, 2026, and is solely responsible for the information contained therein. (C)